Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.
Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide. In the mid-1980s, the median overall survival (OS) for patients with mCRC ranged from 10 to 12 months from the time of initial diagnosis. In more recent studies, this median has more than doubled and is commonly reported at more than 25 to 30 months. These improvements are due, in large part, to the introduction of multiple novel agents during the last 3 decades. Despite these improvements, however, nearly all patients treated with palliative chemotherapy will eventually develop resistance and ultimately succumb to progression of metastatic disease. Understanding the mechanisms by which malignant cells evade treatment could unlock novel therapeutic strategies that overcome resistance and improve survival. In this review, we will discuss some of the drivers of therapeutic resistance in patients with mCRC and present some novel strategies to overcome resistance.
Duke Scholars
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Receptor, erbB-2
- Receptor, ErbB-2
- Proto-Oncogene Proteins p21(ras)
- Proto-Oncogene Proteins B-raf
- Neoplasm Metastasis
- Molecular Targeted Therapy
- Humans
- ErbB Receptors
- Drug Resistance, Neoplasm
- Colorectal Neoplasms
Citation
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Receptor, erbB-2
- Receptor, ErbB-2
- Proto-Oncogene Proteins p21(ras)
- Proto-Oncogene Proteins B-raf
- Neoplasm Metastasis
- Molecular Targeted Therapy
- Humans
- ErbB Receptors
- Drug Resistance, Neoplasm
- Colorectal Neoplasms